



4-1-2018

High-throughput screen of drug repurposing library identifies inhibitors of *Sarcocystis neurona* growth

Gregory D. Bowden
Washington State University,

Kirkwood M. Land
University of the Pacific, kland@pacific.edu

Roberta M. O'Connor
Washington State University

Heather M. Fritz
University of California Davis, Davis

Follow this and additional works at: <https://scholarlycommons.pacific.edu/cop-facarticles>



Part of the [Biology Commons](#)

Recommended Citation

Bowden, G. D., Land, K. M., O'Connor, R. M., & Fritz, H. M. (2018). High-throughput screen of drug repurposing library identifies inhibitors of *Sarcocystis neurona* growth. *Int J Parasitol Drugs Drug Resist*, 8(1), 137–144. DOI: [10.1016/j.ijpddr.2018.02.002](https://doi.org/10.1016/j.ijpddr.2018.02.002)
<https://scholarlycommons.pacific.edu/cop-facarticles/788>

This Article is brought to you for free and open access by the All Faculty Scholarship at Scholarly Commons. It has been accepted for inclusion in College of the Pacific Faculty Articles by an authorized administrator of Scholarly Commons. For more information, please contact mgibney@pacific.edu.



High-throughput screen of drug repurposing library identifies inhibitors of *Sarcocystis neurona* growth

Gregory D. Bowden^a, Kirkwood M. Land^b, Roberta M. O'Connor^{a,*,1}, Heather M. Fritz^{c,**,1}

^a Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, USA

^b Department of Biological Sciences, University of the Pacific, Stockton, CA, USA

^c Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California Davis, Davis, CA, USA

ARTICLE INFO

Keywords:

Drug repurposing
High-throughput screen
Sarcocystis neurona
Equine protozoal myeloencephalitis

ABSTRACT

The apicomplexan parasite *Sarcocystis neurona* is the primary etiologic agent of equine protozoal myeloencephalitis (EPM), a serious neurologic disease of horses. Many horses in the U.S. are at risk of developing EPM; approximately 50% of all horses in the U.S. have been exposed to *S. neurona* and treatments for EPM are 60–70% effective. Advancement of treatment requires new technology to identify new drugs for EPM. To address this critical need, we developed, validated, and implemented a high-throughput screen to test 725 FDA-approved compounds from the NIH clinical collections library for anti-*S. neurona* activity. Our screen identified 18 compounds with confirmed inhibitory activity against *S. neurona* growth, including compounds active in the nM concentration range. Many identified inhibitory compounds have well-defined mechanisms of action, making them useful tools to study parasite biology in addition to being potential therapeutic agents. In comparing the activity of inhibitory compounds identified by our screen to that of other screens against other apicomplexan parasites, we found that most compounds (15/18; 83%) have activity against one or more related apicomplexans. Interestingly, nearly half (44%; 8/18) of the inhibitory compounds have reported activity against dopamine receptors. We also found that dantrolene, a compound already formulated for horses with a peak plasma concentration of 37.8 ± 12.8 ng/ml after 500 mg dose, inhibits *S. neurona* parasites at low concentrations (0.065 μ M [0.036–0.12; 95% CI] or 21.9 ng/ml [12.1–40.3; 95% CI]). These studies demonstrate the use of a new tool for discovering new chemotherapeutic agents for EPM and potentially providing new reagents to elucidate biologic pathways required for successful *S. neurona* infection.

1. Introduction

The apicomplexan parasite *Sarcocystis neurona* is the primary etiologic agent of equine protozoal myeloencephalitis (EPM) (Dubey et al., 1991). In addition to causing progressive neurologic disease in horses, *S. neurona* has also been known to cause encephalitis in Pacific harbor seals (*Phoca vitulina richardsi*), sea otters (*Enhydra lutis*), Pacific harbor porpoises (*Phocoena phocoena*), California sea lions (*Zalophus californianus*) and other marine mammals (Lapointe et al., 1998; Lindsay et al., 2001b; Miller et al., 2001; Carlson-Bremer et al., 2012; Barbosa et al., 2015). *S. neurona* encephalitis has also been reported in other domestic and wild animals including, but not limited to: cats, dogs, raccoons, minks, ferrets, fishers, lynxes and skunks (Dubey et al., 2015).

S. neurona has a complex life cycle which utilizes both a definitive host and an intermediate host. The only known definitive hosts of *S.*

neurona are the North and South American opossums (*Didelphis virginiana* and *Didelphis albiventris*, respectively) (Fenger et al., 1995; Dubey et al., 2001a). Intermediate hosts of *S. neurona* are defined as hosts in which mature sarcocysts, or tissue cysts, have been demonstrated and are a source of infection for definitive hosts. Proven intermediate hosts of *S. neurona* include: cats (Turay et al., 2002), skunks (Cheadle et al., 2001b), raccoons (Lindsay et al., 2001a), sea otters (Dubey et al., 2001c) and armadillos (Cheadle et al., 2001a). Sexual reproduction of the parasite in the intestinal epithelium of the opossum results in development of infectious sporocysts, that are released into the environment via feces. As strict herbivores, horses become infected by ingesting *S. neurona* sarcocysts present on contaminated pasture and feed. Horses are considered aberrant hosts since tissue cyst formation has not been commonly observed in these animals (Dubey et al., 2001b). While details of infection and pathogenesis in horses is still

* Corresponding author. 100 Dairy Rd, Bustad 302, Pullman, WA 99164, USA.

** Corresponding author. One Shields Avenue, VM3A 4206, Davis, CA 95616, USA.

E-mail addresses: roboconnor@vetmed.wsu.edu (R.M. O'Connor), hmfriz@ucdavis.edu (H.M. Fritz).

¹ These authors contributed equally to this work.

poorly understood, it is generally accepted that progressive neurologic disease develops when the parasites gain access to the central nervous system where they cause inflammation and nerve cell death.

Historically, horses suspected to be infected and displaying clinical signs compatible with *S. neurona* were treated with the traditional antiprotozoal drug pyrimethamine in combination with sulfadiazine. These compounds work synergistically and specifically to inhibit parasite folic acid metabolism and nucleotide biosynthesis which are necessary for parasite replication. However, the success rate with the FDA-approved formulation of pyrimethamine and sulfadiazine treatment of EPM has been estimated to be 60%–70% and the relapse rate to be 10% (Reed and Saville, 1996). After *in vitro* cultivation of *S. neurona* parasites was achieved in 1991 testing of potential therapeutic compounds became possible (Dubey et al., 1991). Since then, several additional compounds have been used in the treatment of EPM including: diclazuril, ponazuril, nitazoxanide and decoquinate (Dirikolu et al., 1999, 2006; MacKay et al., 2000; Mitchell et al., 2005; Lindsay et al., 2013). Both diclazuril and ponazuril are FDA-approved benzeneacetone nitrile compounds related to the herbicide atrazine and are hypothesized to act by inhibiting the apicoplast (a derived non-photosynthetic plastid found in most apicomplexa) and/or mitochondrial function in the parasite (Mitchell et al., 2005). Nitazoxanide, an antiparasitic compound with broad activity against protozoa, nematodes, and bacterial pathogens (Dubreuil et al., 1996; Megraud et al., 1998; Theodos et al., 1998), exhibited *in vitro* activity against *S. neurona*, but was removed from the EPM-treatment market for health concerns related to adverse side effects (Gargala et al., 2009). The antiprotozoal compound decoquinate disrupts electron transport in the mitochondrial cytochrome system of apicomplexans (Nam et al., 2011) and is commonly used to treat coccidiosis in livestock. Recently, decoquinate was determined to have activity against *S. neurona* at low concentrations *in vitro* (Lindsay et al., 2013). Treatment of EPM using decoquinate in combination with the immunomodulator levamisole has been reported to provide significant clinical improvement after 10 days of treatment (Ellison and Lindsay, 2012). However, concerns about this study have been raised (including case selection, clinical assessment, and the diagnostic standards) and additional research using confirmed EPM cases needs to be performed to support the reported efficacy of this therapy (Dubey et al., 2015).

Methods for drug discovery for EPM are lagging behind current technologies. Traditionally, inhibitory effects of compounds against *S. neurona* were measured by *in vitro* merozoite production assays patterned after an assay developed by Lindsay and Dubey in 2000 (Lindsay and Dubey, 2000). These time-consuming and labor-intensive assays were used to characterize the *in vitro* antiprotozoal activity of the currently available EPM drugs and other compounds against *S. neurona* (Lindsay and Dubey, 1999, 2000; Lindsay et al., 2000; Gargala et al., 2005, 2009; Dirikolu et al., 2013; Lindsay et al., 2013). Other studies used 3H-uracil incorporation (Marsh et al., 2001), plaque assay (Kruttlin et al., 2001), or light microscopy and TEM (Mitchell et al., 2005) to describe the inhibitory effects of drugs on *S. neurona*. In recent years, advances in molecular tools (e.g., stable transfection of *S. neurona*) and technology have made it possible to readily screen selective compounds or compound libraries for antiprotozoal activity (Gaji et al., 2006; Dangoudoubiyam et al., 2014; Ojo et al., 2016). In contrast to merozoite production assays, high-throughput screening (HTS) using transgenic parasites is a quick and effective method for identifying inhibitory drug compounds and important drug targets. Recent HTS of drug repurposing libraries against luciferase-expressing *Toxoplasma gondii*, a related apicomplexan parasite, demonstrated that HTS methods are robust and reproducible processes for identifying inhibitory compounds (Jin et al., 2009; Kamau et al., 2012).

The objective of this work was to identify antiprotozoal compounds with activity against *S. neurona* using a HTS procedure. By screening the NIH Clinical Collection library against luciferase-expressing *S. neurona*, we identified many FDA-approved compounds that inhibit *S. neurona*.

2. Methods

2.1. Parasite cultures

Sarcocystis neurona strain SN-UCD1 (a generous gift from Patricia Conrad, University of California – Davis of unknown passage number) was passaged in bovine turbinate cells (BT cells, ATCC CRL-1390, American Type Culture Collection, USA) in RPMI 1640 medium supplemented with HEPES, 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin. Parasite cultures were maintained by transferring approximately 100 µl of supernatant from infected BT monolayers to fresh BT monolayers. Cell and parasite cultures were incubated in a humidified chamber at 37 °C and 5% CO₂. *S. neurona* SN-UCD1 merozoites were harvested from infected flasks by repeated passage through a 22-gauge needle as described previously (Marsh et al., 1998).

2.2. Generation of GFP- and FLUC-expressing *S. neurona* merozoites

S. neurona merozoites expressing the reporter enzymes GFP and firefly luciferase (FLUC) were generated using a standard electroporation method described previously (Soldati and Boothroyd, 1993). Briefly, approximately 1.0×10^7 freshly lysed *S. neurona* merozoites were washed twice in phosphate-buffered saline, resuspended in Cytomix buffer (10 mM KPO₄, 120 mM KCl, 0.15 mM CaCl₂, 5 mM MgCl₂, 25 mM HEPES, 2 mM EDTA) and combined with 25 µg of pGRA2-GFP/pTUB1-FLUC plasmid (Kim et al., 2007) linearized with *NotI* (plasmid generously provided by J. Boothroyd, Stanford University). Electroporation was conducted in a 2-mm gap cuvette at 1.4 kV, 50 Ω using a Gene Pulser Xcell™ electroporation system (Bio-Rad, USA). After electroporation, transfected parasites were transferred to a confluent monolayer of host cells and incubated at 37 °C and 5% CO₂. After formation of GFP-positive parasite plaques (approximately 3 days post transfection), stably transfected parasites expressing reporter genes randomly inserted into the genome were isolated by fluorescence-activated cell sorting (FACS), cloned by two rounds of limiting dilution, and passaged three times as described previously before being used for *in vitro* studies. Intracellular transgenic parasites infecting BT cells in a 35-mm glass-bottom dish 4 DPI were imaged with Leica TCS SP8 X Confocal Microscope. Host and parasite nuclei were visualized using NucBlue™ Live ReadyProbes™ Reagent (Thermo Fisher Scientific, USA).

2.3. Development and validation of HTS method

To determine the optimal parasite concentration, incubation time, and inhibition by positive control drug pyrimethamine for the HTS, the growth of FLUC-expressing *S. neurona* merozoites was evaluated. A standard curve was constructed to determine the relationship between FLUC activity measurement and total parasite count. Serial dilutions of *S. neurona* + GFP/FLUC parasites (36 dilutions ranging from 100 to 8.4×10^5 parasites per well in triplicate) were used to infect BT cells in 96-well, tissue-culture treated, white, optically clear bottom microtiter assay plates. FLUC activity was measured 2 h after infection using the Bright-Glo™ Luciferase Assay System (Promega, USA) following manufacturer's directions. Controls included uninfected host cells, and media only for background subtraction. To examine the growth rate of *S. neurona* + GFP/FLUC parasites, BT cells were infected with 5.0×10^3 to 2.0×10^4 merozoites per well. The assay plates were incubated at 37 °C and 5% CO₂ for 8 days, allowing for approximately 2 rounds of parasite replication as approximately 3 days post infection (DPI) are required to complete one round of asexual replication (Lindsay et al., 1999). FLUC activity was measured every 24 h as described previously. Uninfected BT cells were run in parallel as a negative control.

To prepare a positive control for the HTS, the inhibition efficacy of the antiprotozoal drug pyrimethamine was verified by measuring FLUC

activity of wells of assay plates infected with 2.0×10^4 *S. neurona* + GFP/FLUC parasites treated with 10 μ M pyrimethamine, a concentration reported to be 95% inhibitory (Lindsay and Dubey, 1999), in 0.1% dimethyl sulfoxide (DMSO). FLUC activity was measured as described previously every 2 days for 10 days with infected BT cells treated with 0.1% DMSO as a negative control. The efficacy of pyrimethamine in this assay was confirmed by treating BT cells infected with 2.0×10^4 *S. neurona* + GFP/FLUC parasites with various concentrations of pyrimethamine (50, 45, 40, 35, 30, 25, 20, 15, 10, 5, 2.5, 1.25, 0.625, and 0.5 μ M) or DMSO carrier control. FLUC activity was measured as described 4 DPI. Inhibition of *S. neurona* + GFP/FLUC parasites by pyrimethamine was calculated by comparing FLUC activity of treated and untreated parasites using equation (1).

$$\begin{aligned} \% \text{ inhibition} &= \frac{\mu_{\text{DMSO-treated}} - \mu_{\text{Compound-treated}}}{\mu_{\text{DMSO-treated}}} \times 100\%; \mu \\ &= \text{mean FLUC activity} \end{aligned} \quad (1)$$

Estimation of the half-maximal effective concentration (EC_{50}) for pyrimethamine against *S. neurona* + GFP/FLUC parasite growth was estimated using a four-parametric logistic function of GraphPad Prism 7.00 Software (GraphPad, USA).

To evaluate the ability of the growth assay to identify infected cells treated with a *S. neurona* inhibitor from untreated infected cells, BT cells in 96 well plates were infected with 2.0×10^4 parasites/well and randomly treated with either 10 μ M pyrimethamine ($n = 12$) or 0.1% DMSO ($n = 60$). Three separate assay plates prepared independently were incubated at 37 °C and 5% CO_2 for 4 days before FLUC activity was measured as described previously. The robustness of the HTS method was determined by calculating the Z'-factor, as described by Zhang et al. (1999) using equation (2), for each assay.

$$\begin{aligned} Z' &= 1 - \frac{(3 \cdot \sigma_{\text{infected}} + 3 \cdot \sigma_{\text{uninfected}})}{|\mu_{\text{infected}} - \mu_{\text{uninfected}}|}; \sigma = \text{std. dev.}, \mu \\ &= \text{mean FLUC activity} \end{aligned} \quad (2)$$

2.4. High-throughput screen of chemical compounds

Compounds from the NIH Clinical Collection (NCC) library, provided by the National Institutes of Health Molecular Libraries Roadmap Initiative (obtained through Evotec, San Francisco, CA) were received as 10 mM solutions in 100% DMSO. The 725 compounds were diluted 1:1000 in culture medium before being added to assay plates giving a final compound concentration of 10 μ M in 0.1% DMSO. Controls on each assay plate included wells containing 0.1% DMSO as a negative control, 10 μ M pyrimethamine in 0.1% DMSO as a positive control, and uninfected host cells treated with 0.1% DMSO for FLUC activity background measurement. FLUC activity was measured 4 days post-infection. The NCC library was screened twice on different days using separate parasite preparations. The percent inhibition of *S. neurona* + GFP/FLUC parasites for each compound was calculated using equation (1). Compounds that demonstrated greater than 80% inhibition of parasite growth in either screen were classified as hits and selected for secondary confirmational screening.

2.5. Secondary screening

Compounds identified as hits were recovered from NCC library plates and retested as in the previous screening process using 10 μ M in 0.1% DMSO of each compound in biological duplicate with six technical replicates. Confirmed screening hits included compounds that exhibited greater than 80% inhibition of parasite growth in the secondary screening.

2.6. Cellular toxicity assays

To identify false-positive results due to cellular toxicity indirectly leading to parasite death, the cellular toxicity of confirmed hits was determined. To do this, assay plates were seeded with approximately 2.5×10^4 BT cells per well and incubated at 37 °C and 5% CO_2 for 24 h. The growth media of uninfected growing BT host cells was then replaced with RPMI containing 10 μ M of each compound or 0.1% DMSO control. Treated BT cells were incubated for an additional 3 days after which host cell viability was evaluated using CellTiter-Glo[®] Luminescent Cell Viability Assay (Promega, USA) according to the manufacturer's instructions. Compounds that reduced cell viability by 3 standard deviations as compared to DMSO controls were characterized as toxic and removed from further testing. The 50% toxic concentration (TC_{50}) for each non-toxic confirmed inhibitory compound was estimated by quantifying cell viability of BT cells incubated with 100, 50, 25, or 12.5 μ M for 3 days. The TC_{50} for each compound was estimated using a four-parametric logistic function of GraphPad Prism 7.00 Software (GraphPad, USA).

2.7. Half-maximal effective concentration (EC_{50}) calculation

Non-cytotoxic confirmed *S. neurona*-inhibitory compounds were purchased for additional testing. Altanserin, chloroxine, diphenylcyclopropenone, and pyrimethamine were purchased from Sigma. Thiothixene and 5-fluorouracil were purchased from AK Scientific. Perospirone HCl was purchased from Carbosynth. AM-251, artesunate, azelastine HCl, carmofur, clofazimine, dantrolene, disulfiram, hexachlorophene, perphenazine, prazosin, and primaquine phosphate were purchased from TargetMol. Purchased chemicals were used to prepare 10 mM stock solutions in 100% DMSO. Assay plates seeded with BT cells and infected with 2.0×10^4 *S. neurona* + GFP/FLUC parasites were treated with growth media supplemented with 10, 5, 2.5, 1, 0.5, 0.1, and 0.5 μ M compound or 0.1% DMSO control. Compounds were added to assay plates in triplicate and incubated at 37 °C and 5% CO_2 for 4 days before measuring FLUC activity as before. Estimation of EC_{50} value for each compound was accomplished using a four-parametric logistic function of GraphPad Prism 7.00 Software (GraphPad, USA).

3. Results

3.1. Generation of a clonal FLUC-expressing *S. neurona* parasite line

To establish a clonal line of *S. neurona* merozoites expressing GFP and FLUC without using drug selection, extracellular *S. neurona* UCD1 parasites were electroporated with pGRA2-GFP/pTUB1-FLUC (Kim et al., 2007) and transferred to fresh BT cell monolayers for plaque formation. After the formation of GFP-positive plaques, parasites expressing the GFP reporter were then isolated from non-expressing parasites by FACS before cloning by two rounds of limiting dilution. The resulting 37 potential clones were passaged repeatedly before a stable *S. neurona* + GFP/FLUC clone (Fig. 1A) was identified for use in this screen.

3.2. An accurate and sensitive HTS for *S. neurona*

Development of a HTS for *S. neurona* began with optimizing growth conditions of FLUC-expressing parasites in a multiwell format suitable for screening. To accurately predict inhibition of parasite growth by FLUC activity, both growth and inhibition of transgenic parasites was investigated. The number of *S. neurona* + GFP/FLUC merozoites used to inoculate BT host cell monolayers correlated strongly ($R^2 = 0.942$) with the luminescence output reading (Fig. 1B). Additionally, growth and development of *S. neurona* + GFP/FLUC parasites were consistent with previous observations of *S. neurona* growth *in vitro*, with the completion of one cycle of asexual replication approximately 3 DPI




Fig. 1. *S. neurona* + GFP/FLUC merozoite growth measured by FLUC activity. (A) *S. neurona* + GFP/FLUC parasites infecting BT host cells, viewed with a Leica confocal fluorescent microscope (nuclear staining with NucBlue™ Live ReadyProbes™, bar = 10 μm). (B) Linear relationship between luciferase activity of serially diluted *S. neurona* + GFP/FLUC parasites ($n = 3$ per dilution) after 2 h of infection of BT cells and parasite concentration ($R^2 = 0.942$; 95% CI, grey). (C) Representative luciferase-based growth assay of *S. neurona* + GFP/FLUC parasites infecting BT cells at varying concentrations ($n = 3$ per concentration).

(Lindsay et al., 1999). Infection parameters for the HTS were selected based on the minimal concentration of parasites (2.0×10^4 per well) and time (4 DPI) required to achieve a strong luminescent signal (Fig. 1C). The rapid decline in FLUC activity observed 5 DPI until the end of the growth curve was a result of total disruption of the host cell monolayer by *S. neurona* + GFP/FLUC parasites (Fig. S1).

Inhibition of *S. neurona* + GFP/FLUC parasites by pyrimethamine was demonstrated. Treatment of *S. neurona* + GFP/FLUC parasites with 10 μM pyrimethamine severely diminished FLUC activity throughout the 10-day incubation period, which confirmed the utility of the compound as a positive control for the HTS method (Fig. 2A). Inhibition of *S. neurona* + GFP/FLUC parasites by pyrimethamine was further characterized by calculating the EC_{50} of the compound, which was estimated to be 3.22 μM (95% Confidence interval [CI] = 3.06–3.38 μM) (Fig. 2B). These results are consistent with previous reports that concentrations of pyrimethamine greater than or equal to 10 μM were greater than 95% inhibitory (Lindsay and Dubey, 1999).

To validate the HTS method, the assay's ability to distinguish wells of microtiter plates treated with a *S. neurona*-inhibitory compound from wells treated with DMSO carrier was determined. The robustness of our HTS method was evaluated by calculating the Z' statistical parameter described by Zhang et al. (1999) for three separate validation tests. The Z' parameter describes how much of the difference between the means of sample and control signals is accounted for by the separation band between the two signals. An ideal assay has a Z' score greater than 0.5;

however other successful screens have reported lower scores (Bessoff et al., 2013). The mean Z' score for the *S. neurona* HTS was determined to be 0.637 (Fig. 3) indicating that the assay is highly robust. These results demonstrate our ability to accurately measure growth and inhibition of *S. neurona* + GFP/LUC parasites in a method suitable for HTS of chemical compounds.

3.3. Screen of NCC library

A collection of 725 FDA-approved chemical compounds of the NCC library were screened against *S. neurona* + GFP/FLUC parasites using our validated HTS method. Compounds were screened at 10 μM concentration in two separate biological replicates. Results of both screens are shown as a scatterplot (Fig. 4); the data is also available in Table S1, XLSX file. Of the compounds tested, 26 exhibited greater than 80% inhibition in either screen (3.6% hit rate) and were selected for secondary testing. Twenty-four of the 26 hits from the initial screening were confirmed by secondary testing (7.7% false-discovery rate). Six of the 24 confirmed inhibitory compounds exhibited significant host cell cytotoxicity. Eighteen inhibitory compounds of *S. neurona* + GFP/FLUC merozoites were identified from screening the NCC library (Table 1). Almost all the identified hits were previously unknown inhibitors of *S. neurona*. Pyrimethamine was the only compound identified by this screen that had already been characterized as an inhibitor of *S. neurona* growth.




Fig. 2. Susceptibility of *S. neurona* + GFP/FLUC parasites to pyrimethamine measured by FLUC activity. (A) Measurement of FLUC activity of treated (10 μM pyrimethamine, red) or untreated (0.1% DMSO, blue) *S. neurona* + GFP/FLUC merozoites (2.0×10^4 merozoites per well) in BT cells (three replicates per condition) every two days for 10 days (DPI, days post-infection). (B) *S. neurona* + GFP/FLUC parasites (2.0×10^4 merozoites per well) infecting BT cells were treated with various concentrations of pyrimethamine (0.5–50 μM, $n = 3$ per concentration) and incubated for 4 DPI before measuring FLUC activity. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)




Fig. 3. Developed HTS accurately identifies wells treated with an inhibitor of *S. neurona* growth. *S. neurona* + GFP/FLUC parasites infecting BT cells (2.0×10^4 merozoites per well) in three 96-well plates were randomly treated with either 10 μ M pyrimethamine ($n = 12$ per plate, red) or 0.1% DMSO carrier control ($n = 60$ per plate, blue). Uninfected BT cells were included as a negative control ($n = 24$ per plate, black). Infected and uninfected cells were incubated at 37 °C and 5% CO₂ for 4 days before measuring FLUC activity. The sample measurements (i.e., 96 wells per plate) for each biological replicate are separated by vertical dashed lines. The Z' score for each replicate was calculated using FLUC activity of DMSO-treated parasites (horizontal dashed lines, 3 S.D. below normalized untreated mean) and uninfected BT cells (equation (2)). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)




Fig. 4. HTS identifies compounds of NCC library that inhibit *S. neurona* growth. Screening data from two independent screens of NCC library. Open triangles indicate compounds with host-cell toxicity. The horizontal dotted line represents the 80% inhibition cut-off for selecting screening 'hits' (red) from non-inhibitory compounds (blue). Known inhibitory compound pyrimethamine included as positive control (green). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

4. Discussion

We successfully prepared, validated, and completed the first cell-based HTS for *S. neurona* inhibitors. Our screen identified 18 FDA-approved compounds from the NCC library with anti-*S. neurona* activity. Because the HTS measured a decrease in reporter enzyme activity, which we have equated to parasite concentration, the specific mechanism by which these compounds inhibit *S. neurona* growth in culture remains unknown. It is possible that the compounds inhibit *S. neurona* by interfering with one or more important stages of *in vitro* growth including: attachment, host cell invasion, replication, or egress. These compounds could be parasitocidal or simply growth inhibitory. More investigation is required to determine the specific mechanism of inhibition of these compounds. Although some of the compounds in the NCC library have been reported to be inhibitors of *S. neurona* growth *in vitro*, only pyrimethamine was identified by our screen. Neither

trimethoprim, reported to have an EC₅₀ of 2.5 μ g/ml (approximately 8.6 μ M) for *S. neurona* parasites *in vitro* (Lindsay and Dubey, 1999), nor nitazoxanide, with a reported mean 90% inhibitory activity against *S. neurona* of 1.9 mg/L (approximately 6.2 μ M) (Gargala et al., 2009), were found to be greater than 80% inhibitory in this screen. This unexpected result may be explained by variation in assay methods and/or strain differences. Repeated testing of trimethoprim and nitazoxanide estimated EC₅₀ values to be approximately 19 μ M and 12 μ M respectively, both of which are greater than the 10 μ M used in the screening assay (data not shown).

We also identified several potential growth-enhancing compounds of *S. neurona* reflected by increases in FLUC activity. Possible explanations for these results include: compound treatment increases available resources for parasite growth by inhibiting host cell proliferation or nutrient uptake (i.e., albendazole and thibendazole), treatment increases intracellular ionic composition in host cells for parasite use by frequent channel opening (i.e., zolpidem tartrate), or compounds help stabilize and/or activate the FLUC enzyme independent of effects on either host cells or parasites. Although these results were not confirmed by secondary screening, future investigation into the effect these compounds have of *S. neurona* may provide valuable insight into host cell factors that support parasite growth.

Many of the inhibitory compounds identified in this screen have well-defined mechanisms of action, which may assist in the discovery of important biologic processes required for *S. neurona* infection and intracellular survival. For example, we found many of the inhibitory compounds to have activity against dopamine and/or serotonin receptors. For example, identification of altanserin, a 5-hydroxytryptamine receptor 2A (5-HT_{2A}) antagonist, as an *S. neurona* inhibitor, suggests that host cell serotonin signaling may play a role in the asexual reproduction of *S. neurona* parasites. Additionally, the confirmed inhibitory compounds altanserin, azelastine HCl, chloroxine, disulfiram, hexachlorophene, perphenazine, prazosin, and primaquine phosphate all have reported dopamine receptor activity. We anticipated many screening hits to have dopamine receptor activity because of the high concentration (20%; 148/725) of active compounds in the NCC library. However, almost half of confirmed inhibitory compounds (44%; 8/18) have evidence of dopamine receptor activity. This enrichment of compounds with dopamine receptor activity in the screening results highlights the potential importance of host cell dopamine signaling in *S. neurona* growth. Alternatively, dopamine receptor inhibitors may cross react with an unknown target in *Sarcocystis*.

All the inhibitory compounds identified in this screen are FDA-approved, yet only a few have prescribed use in animals. Dantrolene, the most effective compound against *S. neurona* merozoites in this screen, is a direct acting muscle relaxant used in the prevention and treatment of equine post-anesthetic myositis and equine exertional rhabdomyolysis (Edwards et al., 2003). Use of dantrolene to prevent 'tying up' of exercising horses on the racetrack is common, however this compound is regulated by the Association of Racing Commissioners International and a withdrawal period is required to prevent a positive test. Pharmacokinetic analysis of dantrolene in eight healthy horses estimated the peak plasma concentration for dantrolene dose to be 28.9 ± 21.6 (85.95 nM \pm 64.24 nM) and 37.8 ± 12.8 (112.4 nM \pm 38.07 nM) ng/mL for 500 mg capsules and paste respectively, which occurred at 3.8 h after administration for both formulations (DiMaio Knych et al., 2011). The plasma concentration of dantrolene needed to reach the EC₅₀ concentration for *S. neurona* inhibition (21.9 ng/ml or 65 nM, Table 1) suggests that this compound could be a potential new therapy for EPM. However, a successful EPM treatment needs to penetrate the CNS of infected animals as *S. neurona* parasites are found in the CNS in the clinical presentation of horses with EPM. Although there has been controversy as to whether dantrolene can easily penetrate the blood brain barrier and enter the CNS of treated animals, dantrolene has been shown to penetrate the CNS in both primate (Wuis et al., 1989) and

Table 1
Inhibitory compounds of *S. neurona*.

Compound Name	PubChem CID	Description	EC ₅₀ in μM (95% CI)	TC ₅₀ in μM	TI (TC ₅₀ /EC ₅₀)
Altanserin	23581819	5-HT _{2A} -R antagonist	3.5 (2.6–4.5)	> 100 ^a	29
AM-251	2125	CB ₁ antagonist	1.7 (1.4–2.0)	> 100	59
Artesunate	65664	Antimalarial	3.3 (2.8–3.9)	> 100	30
Azelastine HCl	54360	H ₁ -R antagonist	2.5 (2.0–3.0)	28	11
Carmofur	2577	Nucleotide analog	0.73 (0.65–0.81)	> 100	137
Chloroxine	2722	Antibacterial	2.5 (2.2–2.8)	16	6
Clofazimine	2794	Antibacterial	3.7 (3.2–4.2)	> 100	27
Dantrolene	6604100	Channel inhibitor	0.065 (0.036–0.12)	52	800
Diphenylcyclopropenone	65057	Immunomodulator	2.5 (1.2–5.4)	19	8
Disulfiram	3117	ALDH inhibitor	0.15 (0.074–0.31)	20	133
Fluorouracil	3385	Nucleotide analog	0.79 (0.75–0.83)	78	99
Hexachlorophene	3598	Antibacterial	2.8 (2.2–3.6)	56	20
Perospirone HCl	115367	Dopamine-R antagonist	3.4 (2.6–4.2)	86	25
Perphenazine	4748	Dopamine-R antagonist	3.3 (2.8–3.8)	14	4
Prazosin	19846442	Andrenergic α_1 -R antagonist	6.0 (4.1–7.8)	45	8
Primaquine phosphate	359247	Antimalarial	2.2 (1.7–2.6)	47	21
Pyrimethamine	4993	DHFR inhibitor	3.9 (3.6–4.2)	> 100	26
Thiothixene	941651	Dopamine-R antagonist	6.3 (3.2–9.3)	30	5

^a Maximum compound concentration tested.

murine (Wei and Perry, 1996; Chen et al., 2008; Enokizono et al., 2008; Peng et al., 2012) models. The ability of dantrolene to penetrate the CNS of treated horses has yet to be determined. Dantrolene binds to calcium receptors in muscle fiber and interferes with excitation-contraction coupling. We hypothesize that the disruption of intracellular calcium by dantrolene possibly inhibits the life cycle of *S. neurona* merozoites by disrupting the function of crucial parasite calcium-dependent protein kinases (CDPKs). Apicomplexan parasites contain a diverse family of CDPKs that are involved in many cellular pathways including attachment, invasion, and egress. Genomic studies have identified 8 orthologs of *S. neurona* CDPKs in *T. gondii* including TgCDPK1 (Murungi and Kariithi, 2017). Inhibition of TgCDPK1 disrupts host cell invasion and egress of *Toxoplasma* parasites (Lourido et al., 2010).

We also sought to identify inhibitory compounds of *S. neurona* with inhibitory action against other related apicomplexan parasites. The NCC library is publicly available and has been used in a similar HTS method to identify inhibitors of *Cryptosporidium parvum* (Bessoff et al., 2013). Additionally, many of the compounds in the NCC library were included in a drug-repurposing HTS of *T. gondii* (Dittmar et al., 2016) and various anti-*Plasmodium falciparum* testing. Searching the PubChem BioAssay database (Wang et al., 2017) for biological activity of NCC library compounds against *P. falciparum* and *T. gondii* revealed many additional inhibitory compounds of these parasites. We also completed a preliminary screen of confirmed inhibitory compounds of *S. neurona* with no available data against FLUC expressing *T. gondii* (Bowden, unpublished data). All NCC library compounds with available activity data against *P. falciparum* (123/725 compounds) were identified as inhibitors of *P. falciparum* growth. Of the compounds with activity data against *T. gondii* (127/725 compounds), only 22 compounds of the NCC library are classified as inhibitors of parasite growth. In comparing the activity data of library compounds against apicomplexan parasites (Fig. 5), we found only carmofur and 5-fluorouracil to be active against all four parasites; the data is also available in Table S2, XLSX file. Carmofur is a derivative of 5-fluorouracil and both compounds are nucleotide analogs commonly used as chemotherapies. Currently, topical 5-fluorouracil is used to treat squamous cell carcinoma, melanoma, and sarcoids of horses. However, due to the cellular toxicity of both carmofur and 5-fluorouracil, these compounds could not be used as a treatment for EPM. Interestingly, almost all inhibitory compounds of *S. neurona* identified in this screen (15/18; 83%) had activity against at least one parasite considered in this comparison. It is possible that the remaining inhibitory compounds are not actually unique to *S. neurona*, as the activity data for all the NCC library compounds against




Fig. 5. Comparison of activity of NCC compounds against apicomplexan parasites. Number of compounds with shared inhibitory activity against one or more apicomplexan parasite listed in diagram. The total number of compounds of the NCC library (725 compounds total) with available activity data against each parasite is shown in parentheses below the parasite name.

T. gondii and *P. falciparum* in this comparison were not available.

The HTS method developed and validated in this work has the potential to improve the way drug compounds for treatment of EPM are identified and verified *in vitro* prior to *in vivo* trials in available murine models (Witonsky et al., 2005; Dubey et al., 2013) and clinical trials in horses. This advancement employs the current technologies available for drug discovery, and has aided in the identification of novel therapeutic agents for EPM. We identified several compounds in this screen that demonstrated greater *S. neurona* inhibition *in vitro* at lower concentrations than compounds which are currently being used to treat EPM. Certainly, a targeted screen of related chemical compounds, for example inhibitors of CDPKs (Ojo et al., 2016; Hulverson et al., 2017) would yield additional insight into *S. neurona* biology.

Beyond similarities to other apicomplexan parasites, little is known about critical biologic processes in *S. neurona*. Genomic studies have identified conservation of attachment and invasion machinery between *T. gondii* and *S. neurona*, yet substantial differences between the two parasites remain (Blazejewski et al., 2015). For example, *T. gondii* uses an expanded repertoire of effector proteins (e.g., microneme, rhoptry, dense granule) to modulate host cell processes and evade immune detection while residing in a parasitophorous vacuole in the host cell, whereas *S. neurona* lacks many important effector proteins, rhoptries (secretory organelles), and forgoes the development of a parasitophorous vacuole during invasion and intracellular growth. Future investigation into defining the specific mechanism of action of the most promising inhibitory compounds identified by our screen, and *in vivo*

confirmatory studies are required. This information will aid in characterizing important and potentially unique pathway(s) and/or target (s) within *S. neurona* for the development of a novel drugs for EPM.

Acknowledgements

The authors wish to thank Dr. Patricia Conrad of the University of California – Davis for the *S. neurona* UCD1 strain and Dr. John Boothroyd of Stanford for the of pGRA2-GFP/pTUB1-FLUC plasmid. This research was funded in part by the United States Equestrian Federation, and the USA Equestrian Trust (201301890) and the Center for Equine Health, UC Davis (1314). This work was also supported in part by funds from the Washington State University College of Veterinary Medicine and Department of Veterinary Microbiology and Pathology to RMO and HF.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.jipddr.2018.02.002>.

References

- Barbosa, L., Johnson, C.K., Lambourn, D.M., Gibson, A.K., Haman, K.H., Huggins, J.L., Sweeny, A.R., Sundar, N., Raverty, S.A., Grigg, M.E., 2015. A novel *Sarcocystis neurona* genotype XIII is associated with severe encephalitis in an unexpectedly broad range of marine mammals from the northeastern Pacific Ocean. *Int. J. Parasitol.* 45, 595–603.
- Bessoff, K., Sateriale, A., Lee, K., Huston, C.D., 2013. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block *Cryptosporidium parvum* growth. *Antimicrob. Agents Chemother.* 57, 1804–1814.
- Blazejewski, T., Nursimulu, N., Pszeny, V., Dangoudoubyam, S., Namasivayam, S., Chiasson, M.A., Chessman, K., Tonkin, M., Swapna, L.S., Hung, S.S., Bridgers, J., Ricklefs, S.M., Boulanger, M.J., Dubey, J.P., Porcella, S.F., Kissinger, J.C., Howe, D.K., Grigg, M.E., Parkinson, J., 2015. Systems-based analysis of the *Sarcocystis neurona* genome identifies pathways that contribute to a heteroxenous life cycle. *mBio* 6.
- Carlson-Bremer, D.P., Gulland, F.M., Johnson, C.K., Colegrove, K.M., Van Bonn, W.G., 2012. Diagnosis and treatment of *Sarcocystis neurona*-induced myositis in a free-ranging California sea lion. *J. Am. Vet. Med. Assoc.* 240, 324–328.
- Cheadle, M.A., Tanhauser, S.M., Dame, J.B., Sellon, D.C., Hines, M., Ginn, P.E., MacKay, R.J., Greiner, E.C., 2001a. The nine-banded armadillo (*Dasypus novemcinctus*) is an intermediate host for *Sarcocystis neurona*. *Int. J. Parasitol.* 31, 330–335.
- Cheadle, M.A., Yowell, C.A., Sellon, D.C., Hines, M., Ginn, P.E., Marsh, A.E., MacKay, R.J., Dame, J.B., Greiner, E.C., 2001b. The striped skunk (*Mephitis mephitis*) is an intermediate host for *Sarcocystis neurona*. *Int. J. Parasitol.* 31, 843–849.
- Chen, X., Tang, T.S., Tu, H., Nelson, O., Pook, M., Hammer, R., Nukina, N., Bezprozvanny, I., 2008. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. *J. Neurosci.* 28, 12713–12724.
- Dangoudoubyam, S., Zhang, Z., Howe, D.K., 2014. Purine salvage in the apicomplexan *Sarcocystis neurona*, and generation of hypoxanthine-xanthine-guanine phosphoribosyltransferase-deficient clones for positive-negative selection of transgenic parasites. *Parasitology* 141, 1399–1405.
- DiMaio Knych, H.K., Arthur, R.M., Taylor, A., Moeller, B.C., Stanley, S.D., 2011. Pharmacokinetics and metabolism of dantrolene in horses. *J. Vet. Pharmacol. Ther.* 34, 238–246.
- Dirikolu, L., Foreman, J.H., Tobin, T., 2013. Current therapeutic approaches to equine protozoal myeloencephalitis. *J. Am. Vet. Med. Assoc.* 242, 482–491.
- Dirikolu, L., Karpiesiuk, W., Lehner, A.F., Hughes, C., Woods, W.E., Harkins, J.D., Boyles, J., Atkinson, A., Granstrom, D.E., Tobin, T., 2006. New therapeutic approaches for equine protozoal myeloencephalitis: pharmacokinetics of diclazuril sodium salts in horses. *Vet. Ther.* 7, 52–63 72.
- Dirikolu, L., Lehner, F., Nattrass, C., Bentz, B.G., Woods, W.E., Carter, W.G., Karpiesiuk, W., Jacobs, J., Boyles, J., Harkins, J.D., Granstrom, D.E., Tobin, T., 1999. Diclazuril in the horse: its identification and detection and preliminary pharmacokinetics. *J. Vet. Pharmacol. Ther.* 22, 374–379.
- Dittmar, A.J., Drozda, A.A., Blader, I.J., 2016. Drug repurposing screening identifies novel compounds that effectively inhibit *Toxoplasma gondii* growth. *mSphere* 1.
- Dubey, J.P., Davis, S.W., Speer, C.A., Bowman, D.D., de Lahunta, A., Granstrom, D.E., Topper, M.J., Hamir, A.N., Cummings, J.F., Suter, M.M., 1991. *Sarcocystis neurona* n. sp. (Protozoa: apicomplexa), the etiologic agent of equine protozoal myeloencephalitis. *J. Parasitol.* 77, 212–218.
- Dubey, J.P., Garner, M.M., Stetter, M.D., Marsh, A.E., Barr, B.C., 2001a. Acute *Sarcocystis falciparum*-like infection in a carmine bee-eater (*Merops nubicus*) and immunohistochemical cross reactivity between *Sarcocystis falciparum* and *Sarcocystis neurona*. *J. Parasitol.* 87, 824–832.
- Dubey, J.P., Howe, D.K., Furr, M., Saville, W.J., Marsh, A.E., Reed, S.M., Grigg, M.E., 2015. An update on *Sarcocystis neurona* infections in animals and equine protozoal myeloencephalitis (EPM). *Vet. Parasitol.* 209, 1–42.
- Dubey, J.P., Lindsay, D.S., Saville, W.J., Reed, S.M., Granstrom, D.E., Speer, C.A., 2001b. A review of *Sarcocystis neurona* and equine protozoal myeloencephalitis (EPM). *Vet. Parasitol.* 95, 89–131.
- Dubey, J.P., Sundar, N., Kwok, O.C., Saville, W.J., 2013. *Sarcocystis neurona* infection in gamma interferon gene knockout (KO) mice: comparative infectivity of sporocysts in two strains of KO mice, effect of trypsin digestion on merozoite viability, and infectivity of bradyzoites to KO mice and cell culture. *Vet. Parasitol.* 196, 212–215.
- Dubey, J.R., Rosypal, A.C., Rosenthal, B.M., Thomas, N.J., Lindsay, D.S., Stanek, J.F., Reed, S.M., Saville, W.J., 2001c. *Sarcocystis neurona* infections in sea otter (*Enhydra lutris*): evidence for natural infections with sporocysts and transmission of infection to opossums (*Didelphis virginiana*). *J. Parasitol.* 87, 1387–1393.
- Dubreuil, L., Houcke, I., Mouton, Y., Rossignol, J.F., 1996. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. *Antimicrob. Agents Chemother.* 40, 2266–2270.
- Edwards, J.G.T., Newton, J.R., Ramzan, P.H.L., Pilsworth, R.C., Shepherd, M.C., 2003. The efficacy of dantrolene sodium in controlling exertional rhabdomyolysis in the Thoroughbred racehorse. *Equine Vet. J.* 35, 707–710.
- Ellison, S., Lindsay, D., 2012. Decoquinatone combined with levamisole reduce the clinical signs and serum SAG 1, 5, 6 antibodies in horses with suspected equine Protozoal myeloencephalitis. *Int. J. Appl. Res. Vet. Med.* 10, 1–7.
- Enokizono, J., Kusuhara, H., Ose, A., Schinkel, A.H., Sugiyama, Y., 2008. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. *Drug Metab. Dispos.* 36, 995–1002.
- Fenger, C.K., Granstrom, D.E., Langemeier, J.L., Stamper, S., Donahue, J.M., Patterson, J.S., Gajadhar, A.A., Marteniuk, J.V., Xiaomin, Z., Dubey, J.P., 1995. Identification of opossums (*Didelphis virginiana*) as the putative definitive host of *Sarcocystis neurona*. *J. Parasitol.* 81, 916–919.
- Gaji, R.Y., Zhang, D., Breathnach, C.C., Vaishnav, S., Striepen, B., Howe, D.K., 2006. Molecular genetic transfection of the coccidian parasite *Sarcocystis neurona*. *Mol. Biochem. Parasitol.* 150, 1–9.
- Gargala, G., Baishanbo, A., Favennec, L., Francois, A., Ballet, J.J., Rossignol, J.F., 2005. Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzofuran derivatives on *Sarcocystis neurona*, *Neospora caninum*, and *Cryptosporidium parvum* development. *Antimicrob. Agents Chemother.* 49, 4628–4634.
- Gargala, G., Le Goff, L., Ballet, J.J., Favennec, L., Stachulski, A.V., Rossignol, J.F., 2009. In vitro efficacy of nitro- and halogeno-thiazolidine/thiadiazolidine derivatives against *Sarcocystis neurona*. *Vet. Parasitol.* 162, 230–235.
- Hulverson, M.A., Vinayak, S., Choi, R., Schaefer, D.A., Castellanos-Gonzalez, A., Vidadala, R.S.R., Brooks, C.F., Herbert, G.T., Betzer, D.P., Whitman, G.R., Sparks, H.N., Arnold, S.L.M., Rivas, K.L., Barrett, L.K., White Jr., A.C., Maly, D.J., Riggs, M.W., Striepen, B., Van Voorhis, W.C., Ojo, K.K., 2017. Bumped-Kinase inhibitors for cryptosporidiosis therapy. *J. Infect. Dis.* 215, 1275–1284.
- Jin, C., Kaewintajak, K., Jiang, J., Jeong, W., Kamata, M., Kim, H.S., Wataya, Y., Park, H., 2009. *Toxoplasma gondii*: a simple high-throughput assay for drug screening in vitro. *Exp. Parasitol.* 121, 132–136.
- Kamau, E.T., Srinivasan, A.R., Brown, M.J., Fair, M.G., Caraher, E.J., Boyle, J.P., 2012. A focused small-molecule screen identifies 14 compounds with distinct effects on *Toxoplasma gondii*. *Antimicrob. Agents Chemother.* 56, 5581–5590.
- Kim, S.K., Karasov, A., Boothroyd, J.C., 2007. Bradyzoite-specific surface antigen SR9 plays a role in maintaining *Toxoplasma gondii* persistence in the brain and in host control of parasite replication in the intestine. *Infect. Immun.* 75, 1626–1634.
- Kruttl, E.A., Rossano, M.G., Murphy, A.J., Vrable, R.A., Kaneene, J.B., Schott 2nd, H.C., Mansfield, L.S., 2001. The effects of pyrantel tartrate on *Sarcocystis neurona* merozoite viability. *Vet. Ther.* 2, 268–276.
- Lapointe, J.M., Duignan, P.J., Marsh, A.E., Gulland, F.M., Barr, B.C., Naydan, D.K., King, D.P., Farman, C.A., Huntingdon, K.A., Lowenstein, L.J., 1998. Meningoencephalitis due to a *Sarcocystis neurona*-like protozoan in Pacific harbor seals (*Phoca vitulina richardsi*). *J. Parasitol.* 84, 1184–1189.
- Lindsay, D.S., Dubey, J.P., 1999. Determination of the activity of pyrimethamine, trimethoprim, sulfonamides, and combinations of pyrimethamine and sulfonamides against *Sarcocystis neurona* in cell cultures. *Vet. Parasitol.* 82, 205–210.
- Lindsay, D.S., Dubey, J.P., 2000. Determination of the activity of diclazuril against *Sarcocystis neurona* and *Sarcocystis falciparum* in cell cultures. *J. Parasitol.* 86, 164–166.
- Lindsay, D.S., Dubey, J.P., Horton, K.M., Bowman, D.D., 1999. Development of *Sarcocystis falciparum* in cell cultures demonstrates that it is different from *Sarcocystis neurona*. *Parasitology* 118 (Pt 3), 227–233.
- Lindsay, D.S., Dubey, J.P., Kennedy, T.J., 2000. Determination of the activity of ponazuril against *Sarcocystis neurona* in cell cultures. *Vet. Parasitol.* 92, 165–169.
- Lindsay, D.S., Nazir, M.M., Maqbool, A., Ellison, S.P., Strobl, J.S., 2013. Efficacy of decoquinatone against *Sarcocystis neurona* in cell cultures. *Vet. Parasitol.* 196, 21–23.
- Lindsay, D.S., Rosypal, A.C., Spencer, J.A., Cheadle, M.A., Zajac, A.M., Rupprecht, C., Dubey, J.P., Blagburn, B.L., 2001a. Prevalence of agglutinating antibodies to *Sarcocystis neurona* in raccoons, *Procyon lotor*, from the United States. *Vet. Parasitol.* 100, 131–134.
- Lindsay, D.S., Thomas, N.J., Rosypal, A.C., Dubey, J.P., 2001b. Dual *Sarcocystis neurona* and *Toxoplasma gondii* infection in a Northern sea otter from Washington state, USA. *Vet. Parasitol.* 97, 319–327.
- Lourido, S., Shuman, J., Zhang, C., Shokat, K.M., Hui, R., Sibley, L.D., 2010. Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in *Toxoplasma*. *Nature* 465, 359–362.
- MacKay, R.J., Granstrom, D.E., Saville, W.J., Reed, S.M., 2000. Equine protozoal myeloencephalitis. *Vet. Clin. N. Am. Equine Pract.* 16, 405–425.

- Marsh, A.E., Barr, B.C., Packham, A.E., Conrad, P.A., 1998. Description of a new neospora species (Protozoa: apicomplexa: sarcocystidae). *J. Parasitol.* 84, 983–991.
- Marsh, A.E., Mullins, A.L., Lakritz, J., 2001. In vitro quantitative analysis of (3)H-uracil incorporation by *Sarcocystis neurona* to determine efficacy of anti-protozoal agents. *Vet. Parasitol.* 95, 241–249.
- Megraud, F., Occhialini, A., Rossignol, J.F., 1998. Nitazoxanide, a potential drug for eradication of *Helicobacter pylori* with no cross-resistance to metronidazole. *Antimicrob. Agents Chemother.* 42, 2836–2840.
- Miller, M.A., Crosbie, P.R., Sverlow, K., Hanni, K., Barr, B.C., Kock, N., Murray, M.J., Lowenstine, L.J., Conrad, P.A., 2001. Isolation and characterization of *Sarcocystis* from brain tissue of a free-living southern sea otter (*Enhydra lutris nereis*) with fatal meningoencephalitis. *Parasitol. Res.* 87, 252–257.
- Mitchell, S.M., Zajac, A.M., Davis, W.L., Kennedy, T.J., Lindsay, D.S., 2005. The effects of ponazuril on development of apicomplexans in vitro. *J. Eukaryot. Microbiol.* 52, 231–235.
- Murungi, E.K., Kariithi, H.M., 2017. Genome-wide identification and evolutionary analysis of *Sarcocystis neurona* protein kinases. *Pathogens* 6.
- Nam, T.G., McNamara, C.W., Bopp, S., Dharia, N.V., Meister, S., Bonamy, G.M., Plouffe, D.M., Kato, N., McCormack, S., Bursulaya, B., Ke, H., Vaidya, A.B., Schultz, P.G., Winzler, E.A., 2011. A chemical genomic analysis of decoquinone, a *Plasmodium falciparum* cytochrome b inhibitor. *ACS Chem. Biol.* 6, 1214–1222.
- Ojo, K.K., Dangoudoubiyam, S., Verma, S.K., Scheele, S., DeRocher, A.E., Yeargan, M., Choi, R., Smith, T.R., Rivas, K.L., Hulverson, M.A., Barrett, L.K., Fan, E., Maly, D.J., Parsons, M., Dubey, J.P., Howe, D.K., Van Voorhis, W.C., 2016. Selective inhibition of *Sarcocystis neurona* calcium-dependent protein kinase 1 for equine protozoal meningoencephalitis therapy. *Int. J. Parasitol.* 46, 871–880.
- Peng, J., Liang, G., Inan, S., Wu, Z., Joseph, D.J., Meng, Q., Peng, Y., Eckenhoff, M.F., Wei, H., 2012. Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. *Neurosci. Lett.* 516, 274–279.
- Reed, S., Saville, W.J., 1996. Equine protozoal encephalomyelitis. In: *Proceedings 42nd Annu Meet Am Assoc Equine Pract*, 1996 ed, pp. 75–79.
- Soldati, D., Boothroyd, J.C., 1993. Transient transfection and expression in the obligate intracellular parasite *Toxoplasma gondii*. *Science* 260, 349–352.
- Theodos, C.M., Griffiths, J.K., D'Onfro, J., Fairfield, A., Tzipori, S., 1998. Efficacy of nitazoxanide against *Cryptosporidium parvum* in cell culture and in animal models. *Antimicrob. Agents Chemother.* 42, 1959–1965.
- Turay, H.O., Barr, B.C., Caldwell, A., Branson, K.R., Cockrell, M.K., Marsh, A.E., 2002. *Sarcocystis neurona* reacting antibodies in Missouri feral domestic cats (*Felis domesticus*) and their role as an intermediate host. *Parasitol. Res.* 88, 38–43.
- Wang, Y., Bryant, S.H., Cheng, T., Wang, J., Gindulyte, A., Shoemaker, B.A., Thiessen, P.A., He, S., Zhang, J., 2017. PubChem BioAssay: 2017 update. *Nucleic Acids Res.* 45, D955–d963.
- Wei, H., Perry, D.C., 1996. Dantrolene is cytoprotective in two models of neuronal cell death. *J. Neurochem.* 67, 2390–2398.
- Witonsky, S.G., Gogal Jr., R.M., Duncan Jr., R.B., Norton, H., Ward, D., Lindsay, D.S., 2005. Prevention of meningo/encephalomyelitis due to *Sarcocystis neurona* infection in mice is mediated by CD8 cells. *Int. J. Parasitol.* 35, 113–123.
- Wuis, E.W., Rijntjes, N.V., Van der Kleijn, E., 1989. Whole-body autoradiography of 14C-dantrolene in the marmoset monkey. *Pharmacol. Toxicol.* 64, 156–158.
- Zhang, J.H., Chung, T.D., Oldenburg, K.R., 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J. Biomol. Screen* 4, 67–73.